Hypoglycaemic effects of the novel antidiabetic agent repaglinide in rats and dogs

British Journal of Pharmacology

Volumn 121, Issue 8, 1997, Pages 1597-1604

  Mark, Michael ^a   Grell, Wolfgang ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Antidiabetic agents; Antihyperglycaemic effects; Hypoglycaemic effects; Repaglinide

Indexed keywords

AG EE 624 ZW; ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; INSULIN; REPAGLINIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DOG; DOSE TIME EFFECT RELATION; DRUG POTENCY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; INSULIN BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RACEMIC MIXTURE; RAT;

ANIMALS; CARBAMATES; DOGS; FEMALE; GLYBURIDE; HYPOGLYCEMIC AGENTS; PIPERIDINES; RATS; RATS, WISTAR; STEREOISOMERISM; SULFONYLUREA COMPOUNDS;

EID: 0030807194     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701307     Document Type: Article

References (21)

1. DRAEGER, E. (1995). Clinical profile of glimepiride. Diab. Res. Clin. Pract., 28, (Suppl) S139-S146.
2. FRØKJAER-JENSEN, J., KOFOD, H. & GODTFREDSEN, S.E. (1992). Mechanism of action of AG-EE 623 ZW, a novel insulinotropic agent. Diabetologia, 35 (Suppl. 1), Abstract 447.
3. FUHLENDORFF, J., CARR, R., KOFOD, H. & RORSMAN, P. (1995a). The mechanism of action of repaglinide differs to sulphonylureas in murine β cells. Pharmacol. Res., 31, 32.
4. FUHLENDORFF, J., SHYMKO, R., CARR, R.D. & KOFOD, H. (1995b). Characterization of the binding sites for the novel antihyperglycaemic drug, repaglinide. Diabetes, 44 (Suppl. 1), Abstract 848.
5. GARRINO, M.G. & HENQUIN, J.C. (1988). Highly potent and stereoselective effects of the benzoic acid derivative AZ-DF 265 on pancreatic β-cells. Br. J. Pharmacol., 93, 61-68.
6. GARRINO, M.G., SCHMEER, W., NENQUIN, M., MEISSNER, H.P. & HENQUIN, J.C. (1985). Mechanism of the stimulation of insulin release in vitro by HB 699, a benzoic acid derivative similar to the non-sulphonylurea moiety of glibenclamide. Diabetologia, 28, 697-703.
7. GEISEN, K. (1988). Special pharmacology of the new sulfonylurea glimepiride. Arzneim.-Forsch/Drug Res., 38, 1120-1130.
8. GEISEN, K., HÜBNER, M., HITZEL, V., HRSTKA, V.E., PFAFF, W., BOSIES, F., REGITZ, G., KÜHNLE, H.F., SCHMIDT, F.H. & WEYER, R. (1978). Acylaminoalkyl-substituierte Benzoe- und Phenylalkansäuren mit blutglukose-senkender Wirkung. Arzneim.-Forsch/Drug Res., 28, 1081-1083.
9. GROMADA, J., DISSING, S., KOFOD, H & FRØKJAER-JENSEN, J. (1995). Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in β TC3 cells and rat pancreatic β cells. Diabetologia, 38, 1025-1032.
10. GUTNIAK, M. & EFENDIC, S. (1982). The mechanism of the acute hypoglycaemic action of glibenclamide and acyl-amino-alkyl benzoic acid (HB 699) in man. Diabetologia, 23, (Suppl. 1), Abstract 122.
11. KOFOD, H. & FUHLENDORFF, J. (1995). Repaglinide compared to glibenclamide in isolated mouse islets by perifusion. Diabetologia, 38 (Suppl. 1), Abstract 753.
12. MALAISSE, W.J. (1995). Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Horm. Metab. Res., 27, 263-266.
13. PANTEN, U., BURGFELD, J., GOERKE, F., RENNICKE, M., SCHWANSTECHER, M., WALLASCH, A., ZÜNKLER, B.J. & LENZEN, S. (1989). Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets. Biochem. Pharmacol., 38, 1217-1229.
14. PROFOZIC, V., BABIC, D., RENAR, I., RUPPRECHT, E., SKRABALO, Z. & MELOKO, Z. (1993). Benzoic acid derivative hypoglycemic activity in non-insulin dependent diabetic patients. Diabetologia, 36 (Suppl. 1), Abstract 701.
15. RIBES, G., TRIMBLE, E.R., BLAYAC, J.P., WOLLHEIM, C.B., PUECH, R. & LOUBATIERES-MARIANI, M.M. (1981). Effect of a new hypoglycaemic agent (HB 699) on the in vivo secretion of pancreatic hormones in the dog. Diabetologia, 20, 501-505.
16. RIBES, G., TRIMBLE, E.R., WOLLHEIM, C.B., BLAYAC, J.P. & LOUBATIERES-MARIANI, M.M. (1983). Stimulation of pancreatic polypeptide secretion in the dog by hypoglycemic agent HB 699. Am. J. Physiol., 244, E380-E384.
17. RUFER, C. & LOSERT, W. (1979). Blood glucose lowering sulfonamides with asymmetric carbon atoms. 3. Related N-substituted carbamoylbenzoic acids. J. Med. Chem., 22, 750-752.
18. TRONIER, B., MARBURY, T.C., DAMSBO, P. & WINDFELD, K. (1995). A new oral hypoglycaemic agent, repaglinide minimises risk for hypoglycaemia in well controlled NIDDM patients. Diabetologia, 38 (Suppl. 1), Abstract 752.
19. 2+-induced insulin release. Med. Sci. Res., 23, 371-372.
20. VERSPOHL, E.J., AMMON, H.P.T. & MARK, M. (1990). Evidence for more than one binding site for sulfonylureas in insulin-secreting cells. J. Pharm. Pharmacol., 42, 230-235.
21. WOLFENBUTTEL, B.H.R., NIJST, L., SELS, J.P.J.E., MENHEERE, P.P.C.A. & MÜLLER, P.G. (1993). Effects of a new oral hypoglycaemic agent, repaglinide on metabolic control in sulphonylurea-treated patients with NIDDM. Eur. J. Clin. Pharmacol., 45, 113-116.